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Summary
-
The prevention and treatment of coronary heart disease (CHD) necessitates vigorous dietary intervention so as 10
lower the serum cho1eslero11evel by at least 6%. Greater decreases in serum cholesterol can bring about reversal of atherosclerosis.
The critical dietary change is the reduction in intake of saturated fat and cholesterol. Some of this fat may be replaced by
unsaturated fats, especial1y monounsaturated fat (olive or canola oil). Fish and the omega-3 fats they contain may also be useful
for the prevention of CHD. The benefits of omega-3 fats occur within a few months and probably involve an anti-thrombotic
effect. There is evidence that the intake of rrans-fatty acids formed by the hydrogenation of oils should be reduced as they are
associated with CHD. Hypolipidaemic drugs may be useful for persons at very high risk of CHD but should general1y be avoided
for primary prevention.
coronary heart disease / omega-] fatty acids / trans fatty acids
INTRODUCTION
The story of dietary fat and coronary heart disease
(CHD) covers the twentieth century. Yet, new
chapters continue to be written. In this paper I
will look at the role of different fats and discuss




There is now convincing evidence that an ele-
vated blood cholesterol level plays a central role
in CHD. (It may be mentioned that the key par-
ameter is blood cholesterol; no one has ever died
from an elevated serum cholesterol).
Law and colleagues recently reanalyzed the evi-
dence concerning the relationship between blood
cholesterol and the risk of CHD. They reported
a much stronger relationship than that generally
reported elsewhere. International studies indicate
that in middle-age a 0.6 mmol/L lower serum
cholesterol (about 10% of Western values) corres-
ponds to a reduced risk of CHD death of 38% in
men and 31 % in women [29,32]. In one study
differences in serum cholesterol were reported to
account for 80% of the ten-fold variation in CHD
risk across 17 countries (30). Similarly, prospec-
tive studies indicate that a 0.6 mmol/L lower
serum cholesterol indicates a reduced risk of
CHD of 54% at age 40, falling to 20% at age 70
[32].
There is convincing evidence that an elevated
blood cholesterol level causes clinical CHD and
that to a large extent this occurs by way of
atherosclerosis. (The important role played by
thrombosis as a mechanism by which high-fat
diets cause clinical CHD will be considered
later). The International Atherosclerosis Project
examined 23,200 autopsied arteries from 14 coun-
tries [37]. An elevated serum cholesterol level
was found to be a strong predictor of athero-
sclerosis [53], Moreover, atherosclerosis was pre-
sent to a more advanced degree in subjects with
CHD [55].
Another approach that has been pioneered in re-
cent years is the use of angiography so as to quan-
tify the extent of atherosclerosis in living people.
Angiograms of 723 men under the age of 40 ad-
mitted to the Cleveland Clinic (Cleveland, OH,
USA) revealed that the extent of arterial closure
steadily increased with the serum cholesterol
level [62].
They are as sick that suifeit wirh too much as they that starve with /lorhing - Shakespeare, Merchant of Venice.
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The above evidence leaves no doubt that a re-
duction in blood cholesterol is the key to both
the prevention and treatment of CHD. Moreover,
it is clear that the large majority of people in most
Western countries have a blood cholesterol level
that places them at risk of CHD.
Much controversy surrounds the question as to
the dividing line between normal and high serum
cholesterol level. Typically, this is placed around
6.2 to 7.0 mmol/L. In fact, strong evidence shows
that atherosclerosis does not develop when the
serum cholesterol is below 4.0 mmol/L but
steadily develops at higher levels [14, 48]. A level
of 5.0 mmollL is clearly atherogenic, albeit con-
siderably less so than one of 6.0 mmoljL. This
was demonstrated by Keys and colleagues in the
1950s [26]. Men in Japan at that time had a diet
containing only 10% of energy as fat. Their serum
cholesterol was 3.9 mmol/L and few had severe
atherosclerosis, even when aged over 60. In con-
trast, Japanese men in California had adopted the
American diet and along with it, the American
levels of serum cholesterol and atherosclerosis.
THERAPY FOR CHD
The standard therapy for an elevated blood
cholesterol level is to reduce the intake of fat and
saturated fat, but only to a modest degree. For
instance, the step I diet advocates a maximum in-
take of fat and saturated fat of 30% and of 10%,
respectively. However, this causes a drop in
serum cholesterol of only about 2% [43,44]. A
major reason for this is poor compliance. This ac-
counts for the failure seen in several trials to
successfully achieve a reduction in CHD. The
Multiple Risk Factor Intervention Trial (MRFIT)
[40] and the European Collaborative Trial [65]
achieved serum cholesterol reductions of under
3% and, not surprisingly, saw little change in
CHD prevalence.
Achieving a clinically significant impact on
CHD demands a statistically significant impact on
blood cholesterol. As pointed out by Temple and
Walker [56] those dietary trials that achieved a
serum cholesterol reduction of more than 6%
were mostly successful in reducing CHD rates.
This conclusion is supported by the results of
drug trials: pharmacological reduction of blood
cholesterol leads to a lowering of CHD rates
[33,34,36,51].
NJ Temple
Overall, the results of controlled trials indicate
that when the blood cholesterol is lowered,
whether by diet or drugs, it takes five years
before the full benefit becomes manifest. By that
time a 0.6 mmollL reduction in serum cholesterol
translates to a 25% reduced risk of CHD [32].
An effective diet to achieve the requisite lower-
ing of blood cholesterol is one containing 20-30%
of energy as fat with saturated fat reduced to 5-
7%. It is important that some of the displaced fat
is replaced by foods rich in soluble fibre, such
as oats, beans and fruit. Such diets can lower the
cholesterol level from 6% to over 20%. Anderson
and colleagues [I] have for many years employed
such high-carbohydrate/high-fibre diets in therapy
not only for hyperlipidaemia but also for obesity
and diabetes.
This dietary strategy was tested, albeit in an
especially strict form, in the Lifestyle Heart Trial
conducted in San Francisco, California [42].
Patients with CHD were randomized to either an
intervention treatment (IT) group or to a usual
care (UC) control group. The IT were prescribed
a lifestyle programme that included a very low-fat
diet (under 10% of energy) with the elimination
of almost all foods of animal origin. The pro-
gramme also included moderate aerobic exercise,
stress management training, smoking cessation
and group support. The UC patients were asked
to follow a more conventional intervention diet
so as to reduce their fat intake to 30% of energy.
Changes in atherosclerotic lesions were assess-
ed by angiography conducted at baseline and after
one year. The average percentage diameter steno-
sis regressed from 40.0 to 37.8% in the IT group
but increased from 42.7 to 46.1 % in the DC
group. Partial reversal (regression) of lesions was
documented in 82% of IT patients but in only
42% of DC patients. These changes reflect the
fall in serum cholesterol of 24% and 5% in the
IT and UC groups, respectively. It is particularly
noteworthy that progression of atherosclerosis
was observed in 53% of UC patients. This de-
monstrates that the standard therapy for CHD
does not heal the condition but, at best, merely
slows the rate at which it worsens.
Another important observation concerned the
frequency of angina; this fell by 90% in the IT
patients but rose by 165% in the DC patients. Im-
provements in angina were observed in only one
month. This suggests that a low-fat diet can im-
prove angina independent of changes in athero-
sclerosis.
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A study in Heidelberg, Germany, also showed
that a low-fat diet together with exercise could
stop the progression of atherosclerosis [52]. Sub-
jects living with stable angina received a fat mod-
ified diet (UC; fat reduced from 37% to 34% of
energy; energy intake reduced by 19%) or a low-
fat diet (IT; fat reduced from 40% to 26% of
energy; energy reduced 27%). The serum
cholesterol was unchanged in the UC group but
fell by 10% in the IT group. Angiography demon-
strated that after one year, fewer subjects in the
IT group had progression (20% vs 42%) while
more showed reversal (30% vs 4%).
The St Thomas Atheroma Regression Study
(STARS) is also of importance as it was the first
randomized, controlled trial to show that diet
alone could reduce blood cholesterol sufficiently
to open blocked coronary arteries [61]. Middle-
aged men in London with CHD and a plasma
cholesterol over 6.0 mmolfL received either usual
care or a low-fat diet. (A third group received diet
plus a hypolipidaemic drug but this group will
not be considered further.) The modified diet re-
duced fat from 42% to 27% of energy and satu-
rated fat from 17% to 9%, while soluble fibre was
markedly increased.
After 39 months, the plasma cholesterol was
unchanged in the UC group but was lowered by
14% in the IT group. Together with this the IT
had an increase in the proportion showing rever-
sal of artery narrowing from 4 to 38%. As in the
Lifestyle Heart Trial the IT group had a marked
fall in angina.
The demonstration that atherosclerosis is re-
versible is a discovery of profound importance.
It indicates that with enough determination the
fundamental problem causing CHD can be solved.
In fact, this had been demonstrated in monkeys
as long ago as 1970 [3].
THE ROLE OF UNSATURATED FATTY
ACIDS
In many diet intervention trials saturated fat has
been replaced by polyunsaturated fat. Quite apart
from their hypocholesterolaemic affect, there is
additional evidence indicating that these fats may
be cardioprotective. Prospective and retrospective
studies have revealed that tissue levels of linoleic
acid, the most common polyunsaturatcd fatty
acid, are lower in CHD cases than in controls
[64]. Changes in national intake of polyunsatu-
rated fat appear to partly explain trends in CHD
mortality rates: intake has climbed considerably
in Australia and the United States where CHD
mortality has fallen most [23].
In recent years the spotlight has turned on
monounsaturated fats. The impetus for investigat-
ing such diets came from studies of the traditional
Mediterranean diet. That diet is typically rich in
olive oil and therefore mono-unsaturated fats.
Keys et a1 [24] demonstrated in their Seven Coun-
tries Study, which was carried out in the 1950s
and 19608, that the Mediterranean countries have
CHD mortality rates two- to three-fold lower than
that found in northern Europe or the United
States.
Further analysis revealed that across the 15 co-
horts there is a correlation of 0.66 between the
ratio of mono-unsaturated fat to saturated fats and
the IS-year mortality rate for CHD [25]. When
this was adjusted for entry values of age, body
mass index, blood pressure, and number of ciga-
rettes smoked, the correlation then climbed to
0.98. This accounts for a remarkable 96% of the
variance in CHD mortality. In other words, these
data indicate that CHD may be greatly reduced
by minimizing the intake of animal fats (and
therefore saturated fat) and replacing them with
olive oil.
For many years it was believed that mono-
unsaturated fats were neutral as regards the serum
cholesterol. However, more recent evidence indi-
cates that they are as effective as polyunsaturated
fats at lowering the serum cholesterol [38].
Rivellese et al [46] fed diets rich in mono-
unsaturated fats to hyperlipidaemic subjects in
Italy. The diets contained either 27% fat, 17%
mono-unsaturated and 4% polyunsaturated, or
36%, 19% and 10%, respectively. Both diets con-
tained only 6-7% saturated fat. Each diet reduced
plasma cholesterol by about 9%. This indicates
that provided the intake of saturated fat is re-
duced, cholesterol control can be achieved with
diets rich in mono-unsatured fat.
Garg et al [16] compared two diets in patients
with type II diabetes. The first was a low fat diet
(30% of energy as fat) and the second contained
45% of energy as fat, much of it being from mono-
unsaturated fat. No differences were seen in
plasma cholesterol, LDL-cholesterol or HDL-cho-
lesterol. However, the low-fat diet caused a raised
plasma level of glucose, insulin and triglyceride
which persisted at 14 weeks. This indicates that
an increased intake of mono-unsaturated fat can
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lower the level of blood cholesterol while avoid-
ing the raised levels of triglyceride, glucose and
insulin that may occur with a low-fat diet, espe-
cial1y in diabetics.
These observations suggest that provided the
intake of saturated fat is sharply reduced, the con-
tent of mono-unsaturated fat may thus be liber-
alized. However, other evidence suggests that we
should be cautious before adopting that view.
First, Anderson et al [I, 2] investigated and re-
viewed the effects of high-carbohydrate diets,
particularly in diabetics. They assert that provided
the fibre intake is high, such diets are thus not
only effective at lowering the blood cholesterol
but also help achieve glycaemic control. Second,
dietary fat is a major cause of obesity and is as-
sociated with various types of cancer [57]. Third,
international studies show that the Western dis-
eases - including CHD, obesity and type II dia-
betes - are rare in those societies where the diet
is rich in carbohydrate and fibre, and low in fat
[8,60].
An increase in the intake of mono-unsaturated
fat, either from olive oil or canol a oil, would
likely increase the acceptability of the diet. Sur-
prisingly, however, subjects in the above Italian
trial preferred the diet with the lower fat content
despite living in a region where olive oil intake
is traditionally high [46J. In the Lifestyle Heart
Trial, also, adherence to and acceptability of a
vegetarian, low-fat diet among cardiac patients
was found to be quite high [7J.
The first priority, both for primary and second-
ary prevention, must be to introduce a diet with
a much reduced intake of saturated fat and
cholesterol. By necessity this means that foods of
animal origin should be eaten sparingly. At the
same time the intake of foods rich in carbohydrate
and fibre, especially fruit and vegetables, needs
to be given much more prominence. If accep-
tability of the diet becomes a problem and people
desire more fat in their diet, then olive or canola
oil are appropriate choices.
OMEGA-3 FATTY ACIDS
Studies on Greenland Inuit (Eskimos) living on
their traditional diets revealed a high intake of
omega-3 fats, a prolonged bleeding time and a
low risk of CHD [6]. These observations led to
the discovery of the role of long-chain omega-3
fats, particularly eicosapentaenoic acid (EPA) and
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docosahexaenoic acid (DHA), as a preventive of
thrombosis.
Supplements of fish oil alter the composition
of the platelet membrane and the balance of
prostaglandin metabolism [49]. As a result the clott-
ing time is slowed and thrombosis is less likely.
The dose of fish oil required to exert a significant
lengthening of the clotting time is about 3-5
grams per day, making this impracticable as an
anti-thrombotic agent for the general population.
However, there is evidence that fish may be a
preventive of CHD at relatively low intakes. The
Zutphen Study, a prospective study in the Nether-
lands, revealed that small amounts of fish are pro-
tective against CHD mortality [27J. In this study
the protection was clearly seen for both fatty fish
and for non-fatty fish. Other studies have also re-
ported that fish or EPA is protective [9,28]. In
the Multiple Risk Factor Intervention Trial, a
nested case-control study, the serum level of
omega-3 fatty acids was negatively related to risk
of CHD [54].
In contrast to these observations, two large
prospective studies in the United States published
in 1995 did not observe a protective relationship
between the intake of fish or omega-3 fats and
risk of CHD [5,39]. One of these studies also re-
ported no relationship between plasma levels of
long-chain omega-3 fats and myocardial infarc-
tion [39]. These negative results do not necessarily
cast doubt on the value of fish or omega-3 fats;
it should be remembered that prospective studies
have also failed to document a direct association
between the intake of saturated fats and CHD.
These results are suggestive that fish and the
long-chain omega-3 fats they contain may be pro-
tective against CHD. This possibility was tested
in the following clinical trial. CHD patients re-
covering from a myocardial infarction were in-
structed to consume two portions of fatty fish per
week, amounting to at least 300 grams [10].
Patients unable to eat sufficient amounts were
given fish oil capsules as a partial or total subs-
titute. The dietary intervention reduced CHD
deaths by one-third. Non-fatal CHD, howevcr,
was not reduced.
One other trial pertinent to omega-3 fats wil1
also be discussed as it produced especially excit-
ing results. The Seven Countries Study had rc-
vealed exceptionally low rates of CHD in the
Greek island of Crete [24J. Renaud, de Lorgeril
and colleagues [13,45] conducted a clinical trial
in Lyon, France, using an intervention diet based
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on the Cretan diet of the 1960s, a diet that was
rich in legumes, fruit, fats (mostly olive oil) but
had little meat.
Subjects recovering from myocardial infarction
were randomized into two groups. The IT group
was instructed to eat more bread, vegetables, le-
gumes, fish and fruit but less meat and no butter
or cream. Subjects received a special margarine
made from canola oil. This resembles olive oil
but has a higher content of omega-3 fats. The sub-
jects were also instructed to use olive oil or
canola oil as the only oil for salads and food pre-
paration.
Compared with UC patients those in the IT
group consumed one-third less saturated fats
(8.3% vs 11.8% of energy), 24% more oleic acid
(mono-unsaturated fat; 12.9% vs 10.4%), one-
third less linoleic acid (the major omega-6 poly-
unsaturated fat; 3.6% vs 5.4%) but 2.5 times more
omega-3 fat (0.89 vs 0.35%).
After 27 months of follow-up, all forms of
cardiovascular disease, including fatal and non-
fatal CHD as well as stroke, were all reduced by
70-80%. Total mortality fell similarly. The com-
ponents of the diet responsible for these highly
impressive results are a matter of conjecture. As
the beneficial impact of the diet was seen within
a few months and serum lipid values were similar
in the two groups, the mechanism is unlikely to
involve reversal of atherosclerosis. This observa-
tion was also made in the previous trial. The most
plausible explanation is that omega-3 fats greatly
reduce the risk of thrombosis. The authors specu-
late that other factors that may be relevant are
the lower intake of saturated fats, the higher in-
take of mono-unsaturated fat, the higher ratio of
omega-3 to omega-6 fats, and the higher intake
of anti-oxidant nutrients.
These two clinical trials have shown highly im-
pressive results by incorporating sources of
omega-3 fats into the diet. There is an urgent need
for further research into this.
THE PROBLEM OF TRANS FATTY ACIDS
Trans fatty acids are formed when oils are hy-
drogenated so as to harden them and reduce the
rate of spoilage by oxidation. As the following
evidence indicates, these fats may increase the
risk of CHD.
Trans fats have been shown to increase the
serum level of total and LDL cholesterol [22,35].
However, Nicolosi and Dietschy [41] have argued
that this is only in relation to oleic and linoleic
acids and that their effect should more accurately
be classed as neutral. Trans fats may also lower
the HDL cholesterol level and have other actions
that increase the risk of CHD.
Several studies have revealed that persons with
an increased intake of trans fats or an increased
adipose tissue level are at a raised risk of CHD
[63]. Intake of margarine, the chief source of
trans fats, has been associated with risk of CHD
in both a case-control study in Greece [59J and
in a prospective study done as part of the
Framingham Study [18J. Two recent studies, how-
ever, produced essentially negative results con-
cerning the relationship between the trans fat
content of adipose tissue and risk of CHD [4,47].
However, in one of these studies, based on
samples from eight European countries and Israel,
there was a relationship between the level of
C 18: 1 trans fatty acid and CHD when the data
from Spain were excluded [4].
Bearing in mind that the intake of trans fats
can be greatly reduced with minimal incon-
venience (eg, by using non-hydrogenated mar-
garine), it would appear wise to advocate a re-
duced usage of these fats.
DRUG THERAPY FOR HYPOLIPIDAEMIA
An alternative approach to the management of
elevated cholesterol levels has been the use of hy-
polipidaemic drugs. Recently, there has been con-
troversy concerning an excess of non-CHD deaths
associated with these drugs. Smith et al [12] re-
examined the results from drug trials and con-
cluded that drugs lead to an excess of non-CHD
deaths which may exceed the numbers of CHD
deaths prevented. Clearly, if this is the case, then
there is little point in using such drugs. With
patients with an elevated serum cholesterol plus
existing CHD (ie, secondary prevention) the risk
of CHD death is likely to be so high that the re-
duced numbers of CHD deaths leads to a net gain.
However, with patients with an elevated serum
cho]esterol but without existing CHD ~ the ma-
jority of potential patients - there is the possi-
bility that drugs may actually kill more people
than they save.
Law et a] [31] analyzed the same data and con-
cluded that hypolipidaemic drugs do not cause an
excess of non-CHD deaths, except in the case of
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clofibrate. Nevertheless, they conclude that
"
cholesterollowering drugs should not be used
in response to mass cholesterol testing but that
they may be used in patients with (CHD)".
Clearly, more evidence is needed before we can
properly identify the patients for whom the bene-
fits of hypolipidaemic drugs will exceed the risks.
Certainly, a patient at exceptionally high risk of
CHD and who has failed to control his blood
cholesterol by diet should be given these drugs.
A typical person in this class is a man with a
serum cholesterol of over 7 mmol/L plus clini-
cally evident CHD. However, the majority of
patients currently being prescribed such drugs are
at a much lower risk (eg, a man with a serum
cholesterol of 6-6.5 mmol/L and who smokes but
without clinically evident CHD). In such cases
prudence would dictate that discretion is the bet-
ter part of valor. A more appropriate intervention
is to put much greater emphasis on dietary inter-
vention.
AN OVERALL STRATEGY
Based on the evidence discussed here, the most
important feature of an anti-CHD diet is the re-
duction of blood cholesterol levels by sharply re-
ducing the intake of saturated fat and cholesterol.
For a person who already has clinical CHD, this
means reducing fat to about 20-25% of energy
and saturated fat to about 6% of energy. In prac-
tice, that translates to a near-vegetarian diet. For
the primary prevention of CHD this diet can be
liberalized but should certainly have well under
30% of energy as fat and less than 8% of energy
as saturated fat. This means that meat should be
lean and eaten in modest amounts at most. Sim-
ilarly, only low-fat milk should be used.
The partial replacement of saturated fats by un-
saturated fats, particularly mono-unsaturated fat,
is acceptable. However, the necessity for weight
control must be borne in mind. Sources of omega-
3 fats, namely fatty fish and canola oil, appear
to be especially valuable but confirmatory evi-
dence is required. Fish is certainly far preferable
to meat. The use of these foods means that the
diet need not be overly restrictive.
Hypolipidaemic drugs have a useful role but
should, as far as possible, be reserved for patients
at especially high risk. Diet and lifestyle change
must be accorded top priority. However, as the
results emerge from never drugs, their use may
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then become appropriate for more and more
people.
Two other aspects of the diet should not be neg-
lected. First, the diet should contain generous
amounts of fruit and vegetables. These supply
anti-oxidant nutrients which appear to playa
valuable protective role against CHD [17]. Sec-
ond, the intake of salt needs to be greatly re-
duced. This is a cheap, safe and effective way to
decrease the risk of CHD and strokc [27]. In fact,
there is probably no other diet or lifestyle change
that can more easily reduce the risk of these two
diseases.
These dietary changes should be considered
part of a lifestyle approach to the prevention and
treatment of CHD. As an integral part of this it
is esential to target smoking and lack of exercise.
Studies of vegetarians provide compelling evi-
dence for the benefits of a lifestyle approach.
Comparative studies indicate that vegetarians
have a lower (more favourable) body weight,
blood pressure and serum cholesterol [50]. An
eleven-year prospective study of German vegetar-
ians revealed that compared with the German
average the mortality rate was reduced by half
for moderate vegetarians and by three-quarters for
strict vegetarians. Cancer and stroke were also
substantially reduced. All cause mortality was re-
duced by about half. Similar findings have been
made in Britain [58]. These low rates of CHD
and other diseases reflect not only a vegetarian
diet but a generally healthier lifestyle. For in-
stance, few of the German vegetarians were
smokers. Perhaps the one clear conclusion is that
a healthy lifestyle leads to greatly reduced disease
and mortality rates.
One of the clear advantages of the treatment
approaches described in this paper is that it car-
ries a much reduced cost. This is particularly im-
portant when we bear in mind that health-care
budgets in many countries are under severe pres-
sure. Gould [19] estimated the cost of various
forms of treatment for CHD (using American fi-
gures based on five years of treatment). Non-in-
vasive treatment costs $8,000 plus a further
$6,000 for drugs. In comparison, angioplasty
costs $35,000 while bypass surgery costs $60,000.
The dietary changes advocated in this paper
may be ideal but they are unlikely to be
acceptable to the majority of symptom-free
people. Indeed, most of the studies where major
changes in diet or other aspects of lifestyle have
been introduced have been on patients who al-
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ready have CHD. For such people compliance is
quite high.
Another group who might be expected to find
lifestyle change acceptable are persons at high
risk of CHD. Certainly, such people should be
given every encouragement to reduce their risk
of CHD. However, targeting this group has two
serious limitations. First, it will only tackle a
minority of future cases of CHD: Rose [49]
pointed out that the 15% of men at high risk of
CHD account for only 32% of future cases. Sec-
ond, even subjects with major risk factors for
CHD seem to be reluctant to change their life-
style. This was shown in two recent British stu-
dies of health promotion in general practice; a
poor response rate was achieved when patients
were given detailed instruction on dietary and
other lifestyle changes [15,20,21].
If the war against CHD is to be won, this will
not occur in the physician's office. Rather, it will
take place at the population level. A new and fast
developing quasi-medical field is health promo-
tion. This investigates the social, economic,
political and organizational sources of disease and
proposes appropriate policies. For instance, in a
forthcoming book I argue that there is an urgent
need for action at the government level to im-
prove people's lifestyles. This includes the use of
taxes and subsidies so as to shift food consump-
tion patterns towards healthier foods (Temple,
submitted for publication). At present national
food policies in most countries are dominated by
questions of economics rather than health.
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